Shanghai ReHui Biopharmaceutical

ReHui Biopharmaceutical is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics for metabolic diseases and oncology. The company was founded by Dr. Jin-Long Chen, a co-founder of NGM Biopharmaceuticals and former Amgen executive, bringing significant expertise in endocrine and metabolic research. ReHui's lead program, RH001, is a highly selective thyroid hormone receptor beta (THR-beta) agonist designed to treat metabolic dysfunction-associated steatohepatitis (MASH) and related lipid disorders. By focusing on validated biological pathways with optimized medicinal chemistry, the company aims to deliver best-in-class treatments for chronic conditions with high unmet medical needs.